Brainomix

Company profile

About Brainomix

Brainomix is an Oxford University spin-out that has revolutionized medical imaging with AI-powered platforms automating validated imaging biomarkers to improve diagnosis and treatment decisions. The company's flagship product, Brainomix 360 Stroke, is the world's most comprehensive stroke imaging solution, trusted by healthcare systems globally to drive better patient outcomes. The platform includes e-ASPECTS for stroke assessment, e-CTA for large vessel occlusion identification, e-CTP for CT perfusion analysis, e-MRI for advanced imaging, and Triage Stroke/LVO for real-time alerts. Building on its stroke care success, Brainomix has expanded into pulmonary medicine with e-Lung, an FDA-cleared AI platform that automatically identifies and quantifies features on CT lung scans, and is exploring cancer applications with fully automated solutions for solid tumor assessment. The company serves health systems, stroke centers, and clinical research organizations across Europe, the UK, and the United States. Brainomix's technology has been deployed nationwide in Wales and is used in leading hospitals across Germany, Italy, Hungary, Poland, Turkey, and other countries. The company partners with pharmaceutical companies and life sciences organizations to improve clinical trial success and foster broader adoption of therapies in stroke, lung fibrosis, and cancer. Founded by Dr. Michalis Papadakis and built on scientific excellence from Oxford, Brainomix continues to push the boundaries of AI-driven healthcare innovation.

Company description · Brainomix official website

Mission. We turn ordinary scans into extraordinary insights, enabling precision medicine for better treatment decisions.